【百利天恒：BL-M11D1临床试验申请获得美国FDA许可】金十数据10月13日讯，百利天恒公告，近日全资子公司SystImmune,Inc.收到美国食品药品监督管理局（简称“FDA”）的通知，BL-M11D1（CD33-ADC）用于治疗复发或难治性急性髓系白血病患者的I期临床试验申请已获得FDA许可。此次BL-M11D1临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.